Can a cancer drug help kidney patients get transplants faster?
NCT ID NCT05017545
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
Some people waiting for a kidney transplant have immune systems that reject most donors, leading to years of waiting. This study tests whether two drugs—carfilzomib (used for multiple myeloma) and belatacept (an immune-suppressing drug)—can reduce that sensitivity. About 21 participants will receive the drugs and be monitored for safety and whether they become eligible for a transplant sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib and belatacept
What this could lead to
If successful, this approach could help highly sensitized patients receive a kidney transplant sooner by lowering their immune barriers.
What could go wrong
This is an early-phase trial with only 21 participants, so results may not apply broadly. The drugs also carry risks of serious infections and infusion reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Transplant Center, Duke University Medical Center
Durham, North Carolina, 27710, United States